Treatment for patients with newly diagnosed multiple myeloma in 2015

详细信息    查看全文

• 作者：Marí ; a-Victoria Mateos^a ; ^{mvmateos@usal.es" class="auth_mail" title="E-mail the corresponding author} ; Enrique M. Ocio^a ; Bruno Paiva^b ; Laura Rosi&ntilde ; ol^c ; Joaquí ; n Martí ; nez-Ló ; pez^d ; Joan Bladé ; ^c ; Juan-José ; Lahuerta^d ; Ramó ; n Garcí ; a-Sanz^a ; Jesú ; s F. San Miguel^b
• 关键词：Multiple myeloma ; Newly diagnosed ; Upfront treatment
• 刊名：Blood Reviews
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：29
• 期：6
• 页码：387-403
• 全文大小：616 K

文摘

Multiple myeloma is the second most frequent haematological disease. The introduction of high-dose melphalan followed by autologous haematopoietic cell transplant (HDT/ASCT) for young patients and the availability of novel agents for young and elderly patients with multiple myeloma have dramatically changed the perspective of treatment. However, further research is necessary if we want to definitively cure the disease. Treatment goals for transplant-eligible and non-transplant-eligible patients should be to prolong survival by achieving the best possible response, while ensuring quality of life. The treatment should be individualized on the basis of host and disease features and better monitoring of the response upon use of high-sensitivity techniques for evaluating residual disease.

For young patients, HDT/ASCT is a standard of care for treatment and its efficacy has been enhanced and challenged by the new drugs. For elderly patients, treatment options were limited to alkylators, but new upfront treatment combinations based on novel agents (proteasome inhibitors and immunomodulatory drugs) combined or not with alkylators have significantly improved outcomes.

Extended treatment for young and elderly patients improves the quality and duration of clinical responses; however, the optimal scheme, appropriate doses and duration of long-term therapy have not yet been fully determined.

This review summarises the progress in the treatment of patients with newly diagnosed multiple myeloma, addressing critical questions such as the optimal induction, early versus late ASCT, consolidation and/or maintenance for young patients, and how we can choose the best option for non-transplant-eligible patients.